Scilex (SCLX)
Commercializes non-opioid treatments for acute and chronic pain.
Something off on this page? Send us feedback.
Markets ZTlido, ELYXYB, and GLOPERBA while developing additional non-opioid pain-treatment candidates. The commercial portfolio combines topical and oral therapies with licensed product rights.
Markets ZTlido, a prescription lidocaine topical system for pain associated with post-herpetic neuralgia, alongside ELYXYB, a ready-to-use celecoxib oral solution for acute migraine in adults, and GLOPERBA, an oral colchicine solution for adult gout-flare prophylaxis. Its commercial activities center on the United States, with ELYXYB rights also covering Canada.
Combines commercialization of approved pain treatments with development of SEMDEXA (SP-102), SP-103, and SP-104. The portfolio has expanded through exclusive licensing and acquired rights, and the operating model depends on acquiring, developing, and commercializing non-opioid products for acute and chronic pain.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $581.0K · Total debt $95.6M · Total assets $253.6M · Shareholders' equity −$308.3M
- Revenue
- $7.6M
- Operating income
- −$29.4M
- Net income
- −$113.5M
No dividends on record.
| Institutions | 8.27% | 702.8K shares | |
|---|---|---|---|
| 71 holders · as of Jun 30, 2026 | |||
| Insiders | 0.23% | 19.5K shares | |
| 7 holders · as of Dec 18, 2024 | |||
| Strategic holders | 19.91% | 1.69M shares | |
| 2 holders · as of Jul 7, 2026 | |||
| Other | 71.59% | 6.08M shares | |
| remainder | |||
8.49M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
SCLX Stock Acquisition JV LLCStrategic10 percent owner | 11.28% | 958,263 | filed Jul 7, 2026 |
Oramed Pharmaceuticals Inc.Strategic | 8.63% | 732,717 | filed May 8, 2025 |
Vanguard Capital Management LLCInstitution | 3.55% | 301,292 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.29% | 109,417 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.54% | 45,822 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 17, 2026 | Henry Ji | director, officer: Exec Chair, CEO and President | −650,000 | $1.20 |
| Apr 16, 2026 | Henry Ji | director, officer: Exec Chair, CEO and President | +3,250,000 | $1.20 |
| Apr 17, 2026 | Stephen Hoi Ma | director, officer: CFO, COO and Secretary | +650,000 | $1.20 |
| Dec 30, 2025 | Scilex Holding Co | 10 percent owner | −9,657,300 | $0.5394 |
| Dec 29, 2025 | Scilex Holding Co | 10 percent owner | −7,310,984 | $0.6555 |
- Teva (ADR)
Generic topical lidocaine patches overlap with ZTlido and planned SP-103
- AbbVie
Acute migraine treatment overlaps through Ubrelvy
- Pfizer
Acute migraine treatment overlaps through Nurtec ODT and Zavzpret
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Scilex | $5.36 | −0.06% | $43.8M | — | 57.4 | 1.4 | −22.8% |
| Teva (ADR) | $39.33 | −0.41% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| AbbVie | $265.01 | −0.10% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Pfizer | $27.90 | −0.11% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Median | 66.8 | 14.1 | 2.7 | +2.6% |